Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
BJU International|August 30, 2021
Robot-assisted salvage seminal vesicle excision for isolated recurrence after low-dose-rate prostate brachytherapyStephen Langley, Christopher Eden, Matthew Perry, et al.BJU International|August 27, 2021
Long-term survival after low-dose-rate brachytherapy for prostate cancer: the Royal Surrey experienceSantiago Uribe-Lewis, Jennifer Uribe, Vincent Bourke, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 13, 2006
Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancerFerran Guedea, Ferran Aguilo, Alfredo Polo, et al.The Lancet. Oncology|December 24, 2013
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trialHelena M Earl, Anne-Laure Vallier, Louise Hiller, et al.The Lancet. Oncology|June 11, 2017
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trialDavid Cameron, James P Morden, Peter Canney, et al.European Urology|October 11, 2014
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)Nicholas David James, Melissa R Spears, Noel W Clarke, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2022
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)Johnathan K Joffe, Fay H Cafferty, Laura Murphy, et al.Lancet (London, England)|January 1, 2016
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D James, Matthew R Sydes, Noel W Clarke, et al.European Urology Oncology|June 4, 2019
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectivenessBeth S Woods, Eleftherios Sideris, Matthew R Sydes, et al.Pageof 2